Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rossi, D
Right arrow Articles by Gaidano, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rossi, D
Right arrow Articles by Gaidano, G
Haematologica, Vol 89, Issue 2, 154-164
Copyright © 2004 by Ferrata Storti Foundation


Journal Article

Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia

D Rossi, D Capello, A Gloghini, S Franceschetti, M Paulli, K Bhatia, G Saglio, U Vitolo, SA Pileri, M Esteller, A Carbone, and G Gaidano

Hematology Unit, Dept. of Medical Sciences and IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.

BACKGROUND AND OBJECTIVES: Aberrant promoter methylation targets CpG islands causing gene silencing. We explored aberrant promoter methylation of genes potentially involved in B-cell malignancies and encoding proteins implicated in DNA repair (O6-methylguanine-DNA methyltransferase, MGMT), detoxification of environmental xenobiotics (glutathione S-transferase P1, GSTP1), apoptosis regulation (death associated protein kinase, DAP-k and caspase 8, CASP8) and cell cycle control (p73). DESIGN AND METHODS: Three hundred and seventeen B-cell malignancies were investigated by methylation-specific polymerase chain reaction (MSP) of MGMT, GSTP1, DAP-k, CASP8 and p73 genes. In selected cases, MSP results were matched to protein expression studies by immunohistochemistry or Western blotting. RESULTS: DAP-k promoter methylation occurred at highest frequency in follicular lymphoma (85.0%) and MALT-lymphoma (72.2%). MGMT methylation targeted both precursor B-cell neoplasia (23.8%) and mature B-cell tumors (27.6%). GSTP1 methylation was commonest in hairy cell leukemia (75.0%), follicular lymphoma (55.5%), Burkitt s lymphoma (52.0%), and MALT lymphoma (50.0%). Methylation of p73 and CASP8 was rare or absent. DAP-k and MGMT methylation caused absent protein expression. INTERPRETATION AND CONCLUSIONS: Methylation of MGMT, DAP-k and GSTP1 represents a major pathogenetic event in several B-cell malignancies. In follicular lymphoma and MALT lymphoma, frequent inactivation of the apoptosis extrinsic pathway through DAP-k methylation may reinforce the survival advantage already conferred by deregulation of the intrinsic apoptotic pathway. Inactivation of GSTP1 in gastric MALT lymphoma represents an additional mechanism favoring accumulation of reactive oxygen species and lymphomagenesis. Finally, the frequency of GSTP1 aberrant methylation in diffuse large B-cell lymphoma prompts studies aimed at verifying the prognostic impact of this epigenetic lesion in these lymphomas.


This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
C S Chim, W W L Chan, and Y L Kwong
Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in acute leukaemias
J. Clin. Pathol., July 1, 2008; 61(7): 844 - 847.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
K. Amara, M. Trimeche, S. Ziadi, A. Laatiri, M. Hachana, and S. Korbi
Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas
Ann. Onc., June 6, 2008; (2008) mdn374v1.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. M. Horton, P. A. Thompson, S. L. Berg, P. C. Adamson, A. M. Ingle, M. E. Dolan, S. M. Delaney, M. Hedge, H. L. Weiss, M.-F. Wu, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of Temozolomide in Pediatric Patients With Refractory or Recurrent Leukemia: A Children's Oncology Group Study
J. Clin. Oncol., November 1, 2007; 25(31): 4922 - 4928.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. Rizzi, M. P. Tschan, C. Britschgi, A. Britschgi, B. Hugli, T. J. Grob, N. Leupin, B. U. Mueller, H.-U. Simon, A. Ziemiecki, et al.
The death-associated protein kinase 2 is up-regulated during normal myeloid differentiation and enhances neutrophil maturation in myeloid leukemic cells
J. Leukoc. Biol., June 1, 2007; 81(6): 1599 - 1608.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. Shi, J. Guo, D. J. Duff, F. Rahmatpanah, R. Chitima-Matsiga, M. Al-Kuhlani, K. H. Taylor, O. Sjahputera, M. Andreski, J. E. Wooldridge, et al.
Discovery of novel epigenetic markers in non-Hodgkin's lymphoma
Carcinogenesis, January 1, 2007; 28(1): 60 - 70.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Secchiero, E. Barbarotto, M. Tiribelli, C. Zerbinati, M. G. di Iasio, A. Gonelli, F. Cavazzini, D. Campioni, R. Fanin, A. Cuneo, et al.
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
Blood, May 15, 2006; 107(10): 4122 - 4129.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. O. Hoque, E. Rosenbaum, W. H. Westra, M. Xing, P. Ladenson, M. A. Zeiger, D. Sidransky, and C. B. Umbricht
Quantitative Assessment of Promoter Methylation Profiles in Thyroid Neoplasms
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4011 - 4018.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. van Doorn, W. H. Zoutman, R. Dijkman, R. X. de Menezes, S. Commandeur, A. A. Mulder, P. A. van der Velden, M. H. Vermeer, R. Willemze, P. S. Yan, et al.
Epigenetic Profiling of Cutaneous T-Cell Lymphoma: Promoter Hypermethylation of Multiple Tumor Suppressor Genes Including BCL7a, PTPRG, and p73
J. Clin. Oncol., June 10, 2005; 23(17): 3886 - 3896.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Hohaus, A. Di Ruscio, A. Di Febo, G. Massini, F. D'Alo', F. Guidi, G. Mansueto, M. T. Voso, and G. Leone
Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma
Clin. Cancer Res., March 15, 2005; 11(6): 2175 - 2179.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.